comparemela.com
  1. Home
  2. Live Updates
  3. Hansa Biopharma - Breaking News

Page 5 - Hansa Biopharma News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Imlifidase met primary endpoint in 16-HMedIdes-12 phase 2 trial in patients with AMR following kidney transplantation

Imlifidase met primary endpoint in 16-HMedIdes-12 phase 2 trial in patients with AMR following kidney transplantation
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Stephanie kenneyPrnewswire hansa biopharmaHansa biopharmaAchim kaufholdKlaus sindahlLos angelesUnited statesthe companyVp global corporate affairsDivision of pediatricAdult nephrology at cedars sinai medical centerNasdaq stockholmChief medical officerPrincipal investigatorAdult nephrologyCedars sinai medical centerStatesthe company

Hansa Biopharma Announces Full Results from 16-HMedIdeS-12 Phase 2 Trial in Patients with Antibody Mediated Rejection Episodes Following Kidney Transplantation

Hansa Biopharma announced full results from the 16-HMedIdeS-12 phase 2 trial in patients with antibody mediated rejection episodes following a kidney transplant demonstrating that imlifidase.

Hansa biopharma

Hansa Biopharma AB: Imlifidase met primary endpoint in 16-HMedIdes-12 phase 2 trial in patients with AMR following kidney transplantation

Hansa Biopharma AB: Imlifidase met primary endpoint in 16-HMedIdes-12 phase 2 trial in patients with AMR following kidney transplantation
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Hansa biopharmaStefan klotterKlaus sindahlStephanie kenneyPrnewswire hansa biopharmaVp global corporate affairsNasdaq stockholmLassen sie

Imlifidase Met Primary Endpoint In 16-Hmedides-12 Phase 2 Trial In Patients With AMR Following Kidney Transplantation

Imlifidase Met Primary Endpoint In 16-Hmedides-12 Phase 2 Trial In Patients With AMR Following Kidney Transplantation
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

Klaus sindahlPrnewswire hansa biopharmaHansa biopharmaStephanie kenneyVp global corporate affairsNasdaq stockholm

Imlifidase met primary endpoint in 16-HMedIdes-12 phase 2 trial in patients with AMR following kidney transplantation

/PRNewswire/ Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), today announced full results from the 16-HMedIdeS-12 phase 2 trial in patients with antibody.

Stephanie kenneyHansa biopharmaPrnewswire hansa biopharmaKlaus sindahlVp global corporate affairsNasdaq stockholm

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.